New hope for patients out of options: experimental cancer drug opens access
NCT ID NCT06797362
Summary
This program provides access to an experimental drug called zidesamtinib for adults with advanced, ROS1-positive cancers, primarily lung cancer. It is for patients who have already tried at least one other targeted therapy and have no other satisfactory treatment options available. The goal is to offer a potential treatment to those who cannot join a formal clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AUSL della Romagna - Ravenna
AVAILABLERavenna, 48121, Italy
-
Antoni van Leeuwenhoek Hospital
AVAILABLEAmsterdam, 1006 BE, Netherlands
-
CHU de Nantes
AVAILABLENantes, Pays de la Loire Region, 44800, France
-
Centre Leon Berard
AVAILABLELyon, Auvergne-Rhône-Alpes, 69008, France
-
Chris O'Brien Lifehouse
AVAILABLECamperdown, New South Wales, 2050, Australia
-
Cross Cancer Institute
AVAILABLEEdmonton, Alberta, T6G 1Z2, Canada
-
Dana-Farber Cancer Institute
AVAILABLEBoston, Massachusetts, 02215, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
AVAILABLEMilan, 20133, Italy
-
Fox Chase Cancer Center
AVAILABLEPhiladelphia, Pennsylvania, 19111, United States
-
GCS IUCT Oncopole
AVAILABLEToulouse, Occitanie, 31059, France
-
Gregorio Marañón General University Hospital
AVAILABLEMadrid, 28007, Spain
-
Hospital Univ Doce de Octubre
AVAILABLEMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
AVAILABLEBarcelona, 08035, Spain
-
IRCCS Istituto Oncologico Veneto
AVAILABLEPadua, 35128, Italy
-
IRCCS Istituto Tumori Giovanni Paolo II
AVAILABLEBari, 70124, Italy
-
Institut Gustave Roussy
AVAILABLEVillejuif, Île-de-France Region, 94800, France
-
Istituto Nazionale Tumori "Regina Elena
AVAILABLERoma, 00144, Italy
-
L'Istituto Europeo di Oncologia S.r.l.
AVAILABLEMilan, 20141, Italy
-
Massachusetts General Hospital
AVAILABLEBoston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
AVAILABLEManhattan, New York, 10065, United States
-
National Cancer Centre Singapore
AVAILABLESingapore, 168583, Singapore
-
National Cheng Kung University Hospital
AVAILABLETainan, 70403, Taiwan
-
National Taiwan University Hospital
AVAILABLETaipei, 100229, Taiwan
-
National University Hospital Singapore
AVAILABLESingapore, 119074, Singapore
-
Netherlands Cancer Institute: NKI
AVAILABLEAmsterdam, 1066 CX, Netherlands
-
Peter MacCallum Cancer Centre
AVAILABLEMelbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
AVAILABLEToronto, Ontario, M5G 2M9, Canada
-
The Christie Hospital
AVAILABLEManchester, M20 4BX, United Kingdom
-
The Royal Marsden Hospital
AVAILABLESutton, Surrey, SM2 5PT, United Kingdom
-
The Royal Marsden Hospital
AVAILABLELondon, SM2 5PT, United Kingdom
-
University Medical Center Groningen
AVAILABLEGroningen, 9713 GZ, Netherlands
-
University of Chicago Medical Center
AVAILABLEChicago, Illinois, 60637, United States
-
University of Colorado Anschutz School of Medicine
AVAILABLEAurora, Colorado, 80045, United States
-
University of Washington / Fred Hutchinson Cancer Center
AVAILABLESeattle, Washington, 98109, United States
-
Uomi Cancer Center-Clinica Tres Torres
AVAILABLEBarcelona, 08017, Spain
Conditions
Explore the condition pages connected to this study.